Search
Rasburicase
go.drugbank.com/drugs/DB00049ApprovedInvestigationalRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified <i>Saccharomyces cerevisiae</i> strain.
Mephentermine
go.drugbank.com/drugs/DB01365ApprovedWithdrawnA sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine ...
Pimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigational[A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals. … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized
Dicoumarol
go.drugbank.com/drugs/DB00266ApprovedDicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.
Categories: Vitamin K AntagonistsAntrafenine
go.drugbank.com/drugs/DB01419ApprovedIt is not widely used as it has largely been replaced by newer drugs.
Tolbutamide
go.drugbank.com/drugs/DB01124ApprovedIt is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin
Flurbiprofen
go.drugbank.com/drugs/DB00712ApprovedInvestigationalFlurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, os...
Econazole
go.drugbank.com/drugs/DB01127ApprovedA broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel.
Riociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.